baxter face limit effect far remain
cautiou share fairli valu
page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
follow spin-off baxalta baxter new
manag team focus increas effici
innov medic product focu result much
improv profit cash flow gener sinc go
forward compani aim roughli organ sale growth
primarili new product geograph launch
double-digit adjust earn per share free cash flow growth
compound annual acquisit could add
prospect
baxter renal acut care technolog support patient
fail organ often kidney segment
compani gener revenu at-hom patient
use periton dialysi pd equip solut
howev also sell hemodialysi product dialysi clinic
continu renal replac therapi crrt organ
support equip intens care unit new renal segment
launch includ kaguya under-penetrated pd market
japan hdx enabl theranova mimic kidney function
close point care pd system greatli reduc solut
ship month acut care baxter launch product
like prismax simplifi burden deliv crrt
baxter pursu ambiti growth strategi roughli doubl
number molecul sell varieti deliveri
wound closur bleed control product new launch
faster prep version flagship hemostat floseal could
help clinician save signific time oper room
medic deliveri nutrit manag turn around
oper recent hurrican regulatori concern
damag baxter reput reliabl supplier critic
pump may boost growth segment well assum
capit equip budget freez hospit client
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
busi segment renal segment sale includ
periton dialysi hemodialysi product chronic ill patient
acut therapi segment offer kidney organ support
tool intens care situat medic deliveri segment
sale sell iv pump administr set solut nutrit
sale offer parenter nutrit therapi
pharmaceut segment sale offer inject drug anesthet
gase compound servic advanc surgeri segment
sale provid hemostast product biosurg sealant contract
manufactur round remain sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
baxter face limit effect far
remain cautiou share fairli valu
baxter report result oper profit line
bit weaker expect
mild shortfal on-going concern
trim expect howev mild
chang enough materi affect fair valu
estim near market price manag
refrain give outlook beyond first quarter
appear shape fairli well baxter
signific uncertainti surround pandem
affect rest baxter result suspect long-
term impact manag especi given
essenti natur baxter healthcar suppli
support narrow moat
complet
baxter bottom-lin result final unveil
investig firm adjust ep versu
expect free cash flow billion versu
expect billion slightli
expect oper trend fourth quarter
quit strong medic deliveri
constant currenc clinic nutrit constant
currenc appear continu rebound
baxter manag gave guidanc
first quarter state much uncertainti surround
full result given evolv situat
posit glad see firm experienc
limit effect far first quarter
despit signific intern oper
quarter baxter expect oper growth
top line similar previous expect
entir year adjust ep
declin year year base factor
oper profit line includ tax rate differenti
nonrep incom first-quart
manag tone rest cautiou
given on-going spread reflect potenti
slowdown demand capit equip includ
acut renal failur equip infus
pump surgery-rel sale includ anesthesia
wound closur bleed control product also
manag highlight suppli chain cost
rise bit supplier certain countri
particularli china itali face obstacl normal
oper addit order make sure essenti
therapi iv solut avail hospit
custom baxter expect carri inventori
usual pandem concern reced
factor trim expect
sale profit cash flow somewhat
howev suspect baxter therapi
at-hom renal care therapi critic care solut
antibiot solut may actual see increas demand
environ
potenti offset factor still
expect baxter grow year term sale profit
free cash flow rate previous
anticip due on-going concern
long run would expect concern revers
time revers remain uncertain cours
consider maintain
fair valu estim baxter view baxter share
fairli valu recent price
fair valu estim baxter remain per share
trim near-term expect due
concern
assumpt larg unchang low-single-digit
growth expect baxter revenu grow
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
assum baxter reach low
end manag target rang margin
expans come continu sell gener
administr cost control gross margin
expans mix benefit manufactur
effici improv profit effici capit
expenditur plan help baxter gener billion
free cash flow billion
notabl free cash flow like constrain
cost baxter increas inventori
use weight averag cost capit around
discount assumpt assum lower-cost debt
becom slightli preval part capit
presenc rel stabl healthcar market
give compani medium uncertainti rate
bull-cas scenario valu baxter per share
scenario assum new product launch
favor price condit greater market penetr
boost sale growth
base-cas scenario see potenti
variabl base-cas forecast nutrit
segment higher-growth acut therapi
advanc surgeri segment although segment
contribut higher growth rate bull scenario
cost-sav estim streamlin manufactur
distribut effort success transit
growth factor push adjust oper margin
slightli high end target
rang free cash flow rise billion
scenario
forecast manag exceed
compound annual segment
expect renal care grow compound annual
volum expect compound annual growth
period baxter medic deliveri segment
success expect infus pump launch help baxter
get back normal growth pattern
beyond
pharmaceut estim baxter ambiti growth
plan lead compound annual growth around
estim nutrit segment
grow compound annual next five year
although new product launch continu domin
respect nich keep growth posit
futur expect acut therapi advanc surgeri
segment somewhat sensit uncertainti
surround therefor trim
expect segment near term
push growth rate
acut therapi advanc surgeri
respect
adjust oper margin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
bear-cas scenario valu baxter per share
scenario assum new product launch
lacklust headwind iv solut nutrit
continu keep sale growth next
five year versu expect base case forecast
gross margin improv materi
expect firm adjust oper margin
exceed well target
free cash flow reach billion
scenario well
baxter dug narrow moat around provid dialysi
inject therapi complex deliveri system
baxter claim top-tier posit product
line typic compet concentr group
peer overal think would difficult new firm
enter nich primarili due switch cost
associ medic equip
intang asset surround proprietari technolog
manufactur process factor form basi
baxter moat gener see long runway
baxter gener econom profit exist
technolog innov pipelin new product
current baxter gener return invest capit
midteen well excess capit cost
firm introduc new technolog aim becom
even effici believ margin could improv
bolster confid baxter abil
gener econom profit long run
renal care segment believ baxter benefit
primarili switch cost relat place equip
intang asset associ proprietari
technolog baxter second-largest provid dialysi
equip relat consum behind freseniu
medic organ offer broad
spectrum dialysi product strength larg lie
separ technolog geograph footprint
periton dialysi product baxter thrive home
set strong presenc emerg market baxter
domin pd medic product market market share
around versu freseniu patient share
altern freseniu lead way hemodialysi
technolog use clinic
share pd equip place baxter structur
payment use equip relat consum
monthli subscript consum tube
solut deliv directli patient baxter
logist network opinion treatment
work patient littl incent switch due
inertia factor surround train around
self-administ treatment compani busi
model creat recur revenu stream
consum place equip baxter proprietari
medic technolog pd abil continu
innov creat moat sourc relat intang asset
baxter pd offer current benefit
differenti cycler sharesourc technolog
commun patient result doctor allow
doctor adjust treatment remot
particularli valuabl rural emerg market
factor current set baxter tool apart
competit pd offer abil innov remain core
intang asset moat sourc case
medic
initi includ point care pd system greatli reduc
solut ship month current weigh
pound hdx dialyz enabl theranova
close mimic kidney function aim
reduc cardiovascular side effect often associ
similar dynam renal care busi exist baxter
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
acut therapi segment sell organ support tool
intens care unit hospit baxter clearli lead
moat acut therapi stem primarili switch
cost relat caregiv train intang asset
similar renal care segment
rel small percentag baxter total sale
estim midsingl digit percentag sale
baxter
sustain competit advantag recur revenu
outsid renal care infus pump medic
technolog help hospit staff primarili nurs
automat administ medic therapi often lead
recur consum sale administr set iv
solut inject therapi infus pump
rel long life seven year give
long period enjoy recur consum sale
pump place pump offer network
softwar help devic becom embed
workflow caregiv
replac cycl hospit often stick familiar
technolog ensur smooth therapi administr
caregiv well overal infus pump place
hospit believ facil unlik creat
workflow disrupt switch new pump provid
devic often consid gpo contract
negoti on-going sale administr set
therapeut solut although altern deliveri
method util inject therapi -- iv
solut nutrit pharmaceut -- could
infus pump repres key recur
revenu associ infus pump technolog
intang asset front technic featur infus
pump relat consum posit neg
affect caregiv workload patient experi
baxter proprietari technolog remain top-tier
posit concentr market second largest
provid also baxter innov pipelin
appear full four new infus pump expect
launch includ new pump platform
includ option larg volum pump syring
administr patient-control analgesia one
pump put baxter par pump
market leader overal infus
pump busi appear add baxter switch cost
intang asset moat sourc rel
concentr market includ former hospira
oper freseniu braun
carefus acquisit
part consum stori infus
pump believ baxter therapeut offer -- iv
solut nutrit gener pharmaceut -- contain
element scale-rel advantag intang asset
well although consid cost advantag
primari moat sourc baxter overal baxter enjoy
top posit iv solut stand lead posit
parenter nutrit excel difficult manufactur
gener pharmaceut anesthesia asept
premix baxter typic face limit competit
target market top-tier competitor market
includ freseniu braun former hospira asset
overal see signific
barrier entri around busi keep
inject market baxter particip quit
concentr competit perspect specif
key peer estim would take
million three year build manufactur facil
would allow new entrant gain enough scale
compet effect iv solut busi
 iv solut market serv primarili three
provid baxter icu medic freseniu se
invest would requir nutrit
gener pharmaceut busi beyond up-front
similarli
larg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
cost on-going cost associ ensur
complianc due stringent regulatori standard remain
high factor contribut signific entri barrier
new competitor highlight recent
shortag iv solut nutrit market
share shift occur primarili exist
player rather invit signific new competit
beyond scale requir compet success iv
solut nutrit pharmaceut busi see
intang asset relat primarili
provid mix benefit reput
requir consid long-term supplier
hospit nich even gener pharmaceut
baxter primarili particip market complex
manufactur administr requir
inhal anesthet inject therapi franchis
baxter typic face competit
competitor primarili due manufactur complex
much higher oral gener exampl
competit price pressur pervas
beyond gener manufactur requir baxter
also excel asept premix product manufactur
requir keep molecul stabl help ensur
safeti product administr offer ready-to-us
inject care set improv patient safeti
reduc time associ administr task
creat valuabl tool nurs doctor
front line care help baxter gener mix
benefit otherwis commodifi market
nutrit product baxter benefit intang
differenti formul deliveri system ad
intang asset see reputational-rel
therapeut offer well
particularli around abil reliabl supplier
essenti therapi hospit gpo negoti
advanc surgeri think firm benefit primarili
intang asset proprietari product
control bleed close wound surgic
procedur baxter occupi second posit
market behind johnson johnson advanc
hemostat sealant flagship tisseel floseal
product remain differenti baxter continu
innov area new launch aim
includ reduc prepar time floseal reduc
sutur time coupler product on-going
innov add sustain segment
baxter segment consist primarili contract
manufactur pharmaceut compani
contribut baxter scale howev view
contract manufactur advantag busi
evolv primarili
baxter moat trend appear stabl
busi compani face competit limit
number peer due difficulti compet
medic product switch cost medic
equip scale requir intang asset
target market gener view baxter compet
innov new product launch across busi line
help baxter broaden market offer remain
top-tier competitor obtain mix-rel benefit
factor give us larg stabl view trend
busi despit price constraint common
healthcar industri posit one
price-sensit busi pharmaceut baxter
ramp invest new molecul gain scale
put level play field larger peer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
view posit moat busi
neg iv nutrit solut baxter recent
suffer reput setback hurrican activ
knock manufactur capac
essenti therapi volum return baxter
reput reliabl supplier critic therapi
appear weaken bit may take time
chang reput hospit protocol wake
recent shortag period overal though view
posit factor pharmaceut neg factor
iv nutrit solut larg offset
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
obaxt new manag team rev
growth engin addit evolutionari
goal major busi line pipelin
includ sever long-term wildcard stock
potenti treat blood-bas cancer
filtrat technolog
oemerg market prime sourc growth
mani baxter product especi periton
dialysi nutrit solut
oth compani continu strive even higher
profit keep earn growth
sale growth forese futur
oalthough baxter product essenti medic
care patient health mani similar
altern limit baxter price power
owhil pull trigger larg deal yet
baxter new manag team shown
appetit acquisit add uncertainti
prospect could reduc balanc sheet
obaxt reput reliabl supplier iv
solut nutrit relat market share may
easi fulli recov recent shortag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
baxter continu oper net leverag significantli
time target net leverag
time even
easili manag debt come due next five
year fulli cover exist cash also on-going free cash
flow billion manag expect
grow billion appear strong give
baxter plenti financi flexibl substanti
financi resourc dispos firm oper
net leverag target think baxter
capac consid capital-alloc activ caus
net leverag rise recent level exampl even
crisi manag highlight
appetit acquisit particularli acquisit target
valuat declin also baxter could return
cash sharehold compani made billion
dividend payment aim return
adjust net incom sharehold go forward
repurchas billion share baxter
repurchas anoth billion author
repurchas billion end baxter view
share under-valued would surpris
see firm repurchas share environ
presenc rel stabl healthcar market
give compani medium uncertainti rate think
baxter shed riskier asset baxalta spin-off
leav well-diversifi compani particip
market limit risk signific disrupt howev
baxter product line particularli iv solut
nutrit product gener inject
commodifi new competitor decid make
substanti invest need enter market
think price pressur manag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
compani
volum increas mix benefit differenti
must innov maintain competit advantag
particularli renal care infus pump acut therapi
appropri product set peer may surpass
baxter technolog enough affect market share
eventu baxter appetit acquisit also appear
increas creat uncertainti around
trajectori could add financi leverag
balanc sheet factor could add risk
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
america corp
fidel manag research compani
share
fund
share
fund
current assign baxter standard stewardship
rate recogn signific out-performance
new manag team deliv sharehold sinc
take split baxalta gener
think baxter asset neglect bit
previou organiz structur manag team
busi qualiti still remain high due
inher competit advantag new manag
team strategi refresh profit
innov perspect remain baxter
busi split jose almeida
previous chairman ceo covidien prior
acquisit replac longtim baxter
chairman ceo robert parkinson jr sinc join baxter
almeida team focus
profit cash flow margin risen
substanti baxter current busi larg
overshadow higher-growth higher-margin baxalta
asset prior split pleas
manag team abl boost profit
line med-tech industri standard short time
would also note almeida appear rev
previous rel dormant innov
engin bode well growth prospect
although view chang posit signific
uncertainti surround new team capit alloc
polici remain concern potenti acquisit
could eras profit gain manag
made past year would also note
team shi repurchas share
recent gener glad see
manag attempt purchas share attract
valuat mani share repurchas made
fair valu opinion sharehold
also awar financi flexibl could declin
pull trigger larg acquisit current
believ baxter capac consid activ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
increas net leverag would want see
firm add much leverag beyond net leverag target
time sustain period given innov
regulatori risk associ target market
strong growth prospect surpris baxter
current dividend pay-out ratio remain target
around adjust net incom growth
prospect slow increas pay-out ratio could add
sharehold return well
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
baxter face limit effect far
remain cautiou share fairli valu
baxter report result oper profit line
bit weaker expect
mild shortfal on-going concern
trim expect howev mild
chang enough materi affect fair valu
estim near market price manag
refrain give outlook beyond first quarter
appear shape fairli well baxter
signific uncertainti surround pandem
affect rest baxter result suspect long-
term impact manag especi given
essenti natur baxter healthcar suppli
support narrow moat
complet
baxter bottom-lin result final unveil
investig firm adjust ep versu
expect free cash flow billion versu
expect billion slightli
expect oper trend fourth quarter
quit strong medic deliveri
constant currenc clinic nutrit constant
currenc appear continu rebound
baxter manag gave guidanc
first quarter state much uncertainti surround
full result given evolv situat
posit glad see firm experienc
limit effect far first quarter
despit signific intern oper
quarter baxter expect oper growth
top line similar previous expect
entir year adjust ep
declin year year base factor
oper profit line includ tax rate differenti
nonrep incom first-quart
manag tone rest cautiou
given on-going spread reflect potenti
slowdown demand capit equip includ
acut renal failur equip infus
pump surgery-rel sale includ anesthesia
wound closur bleed control product also
manag highlight suppli chain cost
rise bit supplier certain countri
particularli china itali face obstacl normal
oper addit order make sure essenti
therapi iv solut avail hospit
custom baxter expect carri inventori
usual pandem concern reced
factor trim expect
sale profit cash flow somewhat
howev suspect baxter therapi
at-hom renal care therapi critic care solut
antibiot solut may actual see increas demand
environ
potenti offset factor still
expect baxter grow year term sale profit
free cash flow rate previous
anticip due on-going concern
long run would expect concern revers
time revers remain uncertain cours
consider maintain
fair valu estim baxter view baxter share
fairli valu recent price
baxter announc strong fourth-quart result
cautiou increas fve slightli jan
oper result expect strength
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
top oper profit line given estim cash
flow gener sinc last major valuat updat
rais fair valu estim per share
howev continu view baxter share
overvalu recent trade around see
signific uncertainti around share
fourth-quart full-year result look roughli line
expect baxter highlight gener
billion sale fourth quarter report
basi oper basi oper
margin would previou guidanc
strength help compani report billion
report basi oper
basi similar expect full year
manag outlook fell
expect suspect conservat may
work outlook baxter expect sale
growth expect oper margin
report basi expect
adjust basi baxter plan
invest product capac relat trump
administr plan promot at-hom treatment
increas demand baxter periton dialysi tool may
boost prospect long run uncertainti surround
plan outflow near term also baxter current
conduct intern account investig
delay financi report oper profit
line cash flow basi sinc overal
factor obscur firm near-term free cash flow
gener somewhat creat uncertainti
around baxter valuat opinion although top-lin
result roughli met expect report
metric howev compani report signific
figur earn per share firm launch
intern investig report foreign currency-
relat item suspect ultim result
inquiri manag given limit magnitud
transact investig stock fallen
earli trade alreadi view baxter share
overvalu anticip chang fair valu
estim base announc
quarter baxter sale grew oper
billion line manag previou
expect report basi segment renal
benefit on-going growth patient serv
quarter off-set somewhat discontinu
hemodialysi product set temporari suppli constraint
revaclear dialyz acut therapi perform well
quarter help launch next gener
prismax system support kidney failur patient
acut care set momentum continu medic
deliveri clinic nutrit seen
improv hurricane-rel issu caus
suppli shortag custom switch advanc
surgeri also turn strong result help competit
bottom line baxter report give outlook
figur oper profit line due on-going
account investig pleas see
adjust oper margin grow quarter
basi point report prior-year
period sinc compani report earn per
share yet remain unclear baxter perform
metric even adjust basi gener would
expect one quarter profit chang view baxter
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
intern account investig appear focus
way baxter account foreign currenc gain
loss sever prior period import
probabl would chang view firm exampl
baxter reveal net foreign exchang gain amount
million million million million
million million year
first half respect
subject investig ultim charg
could larger smaller figur view
firm free cash flow gener probabl would
chang significantli initi estim appear
accur file perspect though compani
expect turn third-quart result
sec time manner like amend previou
file investig complet total
factor obscur firm recent free cash flow gener
somewhat creat uncertainti around baxter
trump administr
compani also would comment specif
expect manag appear somewhat
cautiou given previous announc plan invest
product capac at-hom dialysi equip
advanc american kidney health initi top
periton dialysi pd provid world expect
baxter key beneficiari expans at-hom
therapi unit state given technolog
physician relationship advantag field
increas demand compani pd tool may boost
prospect especi outer year forecast
period uncertainti surround cumul free cash
flow gener near term opinion given
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
